These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 33048883)

  • 1. Asymptomatic neurocognitive impairment is a risk for symptomatic decline over a 3-year study period.
    Rourke SB; Bekele T; Rachlis A; Kovacs C; Brunetta J; Gill MJ; Carvalhal A; Cysique LA; Marcotte T; Power C
    AIDS; 2021 Jan; 35(1):63-72. PubMed ID: 33048883
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Asymptomatic HIV-associated neurocognitive impairment increases risk for symptomatic decline.
    Grant I; Franklin DR; Deutsch R; Woods SP; Vaida F; Ellis RJ; Letendre SL; Marcotte TD; Atkinson JH; Collier AC; Marra CM; Clifford DB; Gelman BB; McArthur JC; Morgello S; Simpson DM; McCutchan JA; Abramson I; Gamst A; Fennema-Notestine C; Smith DM; Heaton RK;
    Neurology; 2014 Jun; 82(23):2055-62. PubMed ID: 24814848
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuropsychological Assessment of 412 HIV-Infected Individuals in São Paulo, Brazil.
    Gascón MRP; Vidal JE; Mazzaro YM; Smid J; Marcusso RMN; Capitão CG; Coutinho EM; Benute GRG; De Lucia MCS; de Oliveira ACP
    AIDS Patient Care STDS; 2018 Jan; 32(1):1-8. PubMed ID: 29323557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence of HIV-associated neurocognitive disorder (HAND) in Turkey and assessment of Addenbrooke's Cognitive Examination Revised (ACE-R) test as a screening tool.
    Korten V; Ay U; Harı E; Tigen Tükenmez E; Gencer S; Akça Kalem S; Demirtaş Tatlıdede A; Gürvit İH
    HIV Med; 2021 Jan; 22(1):60-66. PubMed ID: 32964651
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Contemporary trends in HIV-associated neurocognitive disorders in Ghana.
    Sarfo FS; Kyem G; Asibey SO; Tagge R; Ovbiagele B
    Clin Neurol Neurosurg; 2021 Nov; 210():107003. PubMed ID: 34715557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A decreasing CD4/CD8 ratio over time and lower CSF-penetrating antiretroviral regimens are associated with a higher risk of neurocognitive deterioration, independently of viral replication.
    Vassallo M; Fabre R; Durant J; Lebrun-Frenay C; Joly H; Ticchioni M; DeSalvador F; Harvey-Langton A; Dunais B; Laffon M; Cottalorda J; Dellamonica P; Pradier C
    J Neurovirol; 2017 Apr; 23(2):216-225. PubMed ID: 27815816
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Determining optimal impairment rating methodology for a new HIV-associated neurocognitive disorder screening procedure.
    Kamminga J; Bloch M; Vincent T; Carberry A; Brew BJ; Cysique LA
    J Clin Exp Neuropsychol; 2017 Oct; 39(8):753-767. PubMed ID: 28052738
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HIV associated neurocognitive disorders (HAND) in Malawian adults and effect on adherence to combination anti-retroviral therapy: a cross sectional study.
    Kelly CM; van Oosterhout JJ; Ngwalo C; Stewart RC; Benjamin L; Robertson KR; Khoo S; Allain TJ; Solomon T
    PLoS One; 2014; 9(6):e98962. PubMed ID: 24915530
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Atrophic brain signatures of mild forms of neurocognitive impairment in virally suppressed HIV infection.
    Nichols MJ; Gates TM; Soares JR; Moffat KJ; Rae CD; Brew BJ; Cysique LA
    AIDS; 2019 Jan; 33(1):55-66. PubMed ID: 30325766
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association Between Frailty and HIV-Associated Neurodegenerative Disorders Among Older Adults Living with HIV.
    Zamudio-Rodríguez A; Belaunzarán-Zamudio PF; Sierra-Madero JG; Cuellar-Rodríguez J; Crabtree-Ramírez BE; Alcala-Zermeno JL; Amieva H; Avila-Funes JA
    AIDS Res Hum Retroviruses; 2018 May; 34(5):449-455. PubMed ID: 29385834
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlates of the HIV-associated neurocognitive disorders among adults living with HIV in Dodoma region, central Tanzania: A cross-sectional study.
    Nyundo AA
    PLoS One; 2023; 18(5):e0285761. PubMed ID: 37228133
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is the use of the QPC cognitive complaints questionnaire relevant for the screening strategy of HIV-Associated neurocognitive disorders?
    Zaegel-Faucher O; Laroche H; Tixier M; Morisseau V; Obry-Roguet V; Poizot-Martin I
    AIDS Care; 2021 Mar; 33(3):389-397. PubMed ID: 32279542
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Validation of the International HIV Dementia Scale as a Screening Tool for HIV-Associated Neurocognitive Disorders in a German-Speaking HIV Outpatient Clinic.
    Marin-Webb V; Jessen H; Kopp U; Jessen AB; Hahn K
    PLoS One; 2016; 11(12):e0168225. PubMed ID: 27992497
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Screening Strategy for HIV-Associated Neurocognitive Disorders That Accurately Identifies Patients Requiring Neurological Review.
    Bloch M; Kamminga J; Jayewardene A; Bailey M; Carberry A; Vincent T; Quan D; Maruff P; Brew B; Cysique LA
    Clin Infect Dis; 2016 Sep; 63(5):687-693. PubMed ID: 27325690
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Utility of the International HIV Dementia Scale for HIV-Associated Neurocognitive Disorder.
    Molinaro M; Sacktor N; Nakigozi G; Anok A; Batte J; Kisakye A; Myanja R; Nakasujja N; Robertson KR; Gray RH; Wawer MJ; Saylor D
    J Acquir Immune Defic Syndr; 2020 Mar; 83(3):278-283. PubMed ID: 32032278
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence of HIV-associated neurocognitive disorders in the Multicenter AIDS Cohort Study.
    Sacktor N; Skolasky RL; Seaberg E; Munro C; Becker JT; Martin E; Ragin A; Levine A; Miller E
    Neurology; 2016 Jan; 86(4):334-40. PubMed ID: 26718568
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anemia and Red Blood Cell Indices Predict HIV-Associated Neurocognitive Impairment in the Highly Active Antiretroviral Therapy Era.
    Kallianpur AR; Wang Q; Jia P; Hulgan T; Zhao Z; Letendre SL; Ellis RJ; Heaton RK; Franklin DR; Barnholtz-Sloan J; Collier AC; Marra CM; Clifford DB; Gelman BB; McArthur JC; Morgello S; Simpson DM; McCutchan JA; Grant I;
    J Infect Dis; 2016 Apr; 213(7):1065-73. PubMed ID: 26690344
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIV-Associated Neurocognitive Disorders: The First Longitudinal Follow-Up of a cART-Treated Cohort of Older People in Sub-Saharan Africa.
    Spooner R; Ranasinghe S; Urasa S; Yoseph M; Koipapi S; Mukaetova-Ladinska EB; Lewis T; Howlett W; Dekker M; Kisoli A; Gray WK; Walker RW; Dotchin CL; Kalaria R; Lwezuala B; Makupa PC; Akinyemi R; Paddick SM
    J Acquir Immune Defic Syndr; 2022 Jun; 90(2):214-222. PubMed ID: 35125473
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Virologically suppressed patients with asymptomatic and symptomatic HIV-associated neurocognitive disorders do not display the same pattern of immune activation.
    Vassallo M; Durant J; Lebrun-Frenay C; Fabre R; Ticchioni M; Andersen S; DeSalvador F; Harvey-Langton A; Dunais B; Cohen-Codar I; Montagne N; Cua E; Fredouille-Heripret L; Laffon M; Cottalorda J; Dellamonica P; Pradier C
    HIV Med; 2015 Aug; 16(7):431-40. PubMed ID: 25981452
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sex differences in HIV-associated cognitive impairment.
    Sundermann EE; Heaton RK; Pasipanodya E; Moore RC; Paolillo EW; Rubin LH; Ellis R; Moore DJ;
    AIDS; 2018 Nov; 32(18):2719-2726. PubMed ID: 30407251
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.